Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Wednesday

Minerva Neurosciences (NASDAQ:NERV) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect Minerva Neurosciences to post earnings of ($1.07) per share for the quarter.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.49. On average, analysts expect Minerva Neurosciences to post $0 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Minerva Neurosciences Trading Up 0.6 %

NASDAQ:NERV opened at $1.71 on Tuesday. Minerva Neurosciences has a 12 month low of $1.15 and a 12 month high of $3.69. The firm has a market cap of $11.96 million, a P/E ratio of -3.89 and a beta of -0.09. The stock has a 50 day moving average of $1.62 and a two-hundred day moving average of $2.01.

Wall Street Analyst Weigh In

NERV has been the subject of a number of research reports. HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, February 26th. StockNews.com began coverage on Minerva Neurosciences in a research note on Monday. They set a “sell” rating on the stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.